Hot AXIOS™ per il drenaggio dei dotti biliari nella stenosi maligna (RAINBOW)
Studio prospettico francese sul drenaggio delle vie biliari guidato dall'ecografia endoscopica in pazienti con stenosi biliare maligna (RAINBOW)
The study is designed to highlight the effectiveness of the Hot AXIOS™ stent when used in accordance with standard medical practice on the evolution of the quality of life of patients with malignant biliary stenosis requiring drainage of the bile ducts after failure of ERCP, in the two months after stent placement.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The study will evaluate the quality of life in patients with malignant biliary obstruction after the placement of a lumen-apposing metal stent via endoscopic ultrasound, with an emphasis on the improvement of quality of life measured as a reduction in jaundice. Improvement in jaundice is a direct indicator of effective bile drainage and is expected to correlate with an enhancement in overall quality of life. Quality of life will be measured by means of subject response to the EORTC QLQ-BIL21, a component of the European Organization for Research and Treatment of Cancer (EORTC) designed specifically to assess the quality of life in patients with biliary tract cancer. The QLQ-BIL21 consists of 21 questions which aim to evaluate specific symptoms and issues relevant to patients with biliary tract cancer, such as jaundice, pain, digestive problems and the psychosocial impact of the disease.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Besançon, Francia, 25030
- CHU de Besançon
-
Cornebarrieu, Francia, 31700
- Clinique des Cedres, Ramsay Sante
-
Limoges, Francia, 87042
- CHU Limoges
-
Lyon, Francia, 69008
- Hopital Prive Jean Mermoz
-
Nantes, Francia, 44300
- Clinique Jules Verne
-
Nice, Francia, 06202
- CHU Nice
-
Paris, Francia, 75012
- Hopital Saint Antoine
-
Paris, Francia, 75908
- Hopital Europeen Georges-Pompidou
-
Paris, Francia, 75014
- Hopital Paris Saint-Joseph
-
Poitiers, Francia, 86021
- CHU de Poitiers
-
Reims, Francia, 51092
- CHU Reims
-
Rennes, Francia, 35033
- CHRU Hopital Pontchaillou
-
Rouen, Francia, 76000
- Clinique Saint-Hilaire
-
Saint-Herblain, Francia, 44800
- Santé Atlantique
-
Strasbourg, Francia, 67091
- CHU de Strasbourg
-
Toulouse, Francia, 31059
- CHU Rangueil
-
Vandœuvre-lès-Nancy, Francia, 54500
- CHRU de Nancy
-
Vichy, Francia, 03200
- Centre Hospitalier de Vichy
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients 18 years or older
- Willing and able to comply with study procedures and provide written informed consent
- Patients with failed ERCP for treatment of suspected malignant biliary obstruction
- Patients for whom an indication for Hot AXIOS™ stent placement has been determined
Exclusion Criteria:
- Women who are pregnant, nursing or planning to become pregnant during the study
- Patients with immediately resectable tumor or resectable during the two months of the study
- Patients for whom the placement of a double pigtail prosthesis is planned by the investigator during the index procedure
- Current participation in another investigation drug or device study that could interfere with the endpoints of this study
- Persons under guardianship or curatorship
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Hot AXIOS™ Recipients
The Hot AXIOS™ Stent is a flexible, fully covered self-expanding metal stent that is preloaded within the Electrocautery Enhanced Delivery System. Patients who meet all eligibility criteria will receive the Hot AXIOS™stent and their quality of life will be measured at baseline, two weeks after stent placement and two months after stent placement by the jaundice dimension of the EORTC QLQ-BIL21 questionnaire. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study. |
The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Quality of Life Measurement - Jaundice Dimension
Lasso di tempo: 2 months (± 15 days)
|
The primary outcome is the difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the jaundice dimension consists of three of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Quality of Life Measurement - Non-Jaundice Dimension
Lasso di tempo: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the non-jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the non-jaundice dimension consists of 18 of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Quality of Life Measurement - Global Score
Lasso di tempo: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the global score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much). A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Reduction in Bilirubin (Clinical Success)
Lasso di tempo: 2 weeks (+ 7 days) and 2 months (± 15 days)
|
Clinical success is defined as a reduction in bilirubin > 50% at each follow-up compared to baseline. |
2 weeks (+ 7 days) and 2 months (± 15 days)
|
|
Rate of Resolution of Clinical Symptoms
Lasso di tempo: 2 months (± 15 days)
|
Resolution of GOO-related clinical symptoms such as jaundice, nausea/vomiting, fever/chills, weight loss and abdominal pain following implant of Hot AXIOS™ at 2 months of follow-up |
2 months (± 15 days)
|
|
Rate of Reintervention
Lasso di tempo: 2 months (± 15 days)
|
Reintervention is defined as endoscopic, radiological or surgical intervention for the management of recurrent biliary obstruction due to stent dysfunction (e.g., obstruction or migration) at 2 months of follow-up. This criterion will be measured within the population for whom the placement of the Hot AXIOS™ stent was a technical success. |
2 months (± 15 days)
|
|
Chemotherapy Status
Lasso di tempo: 2 months (± 15 days)
|
Number of days after study stent implantation to start or continuation of chemotherapy (if applicable). |
2 months (± 15 days)
|
|
Overall Survival
Lasso di tempo: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the date of death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure overall survival. |
2 months (± 15 days)
|
|
Progression-Free Survival
Lasso di tempo: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the earliest date of either disease progression or death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure progression-free survival. |
2 months (± 15 days)
|
|
Number of Days Alive after Hospital Discharge
Lasso di tempo: 2 months (± 15 days)
|
Number of days alive after hospital discharge within 2 months after the placement of the Hot AXIOS™. |
2 months (± 15 days)
|
|
Rate of Technical Success
Lasso di tempo: 2 months (± 15 days)
|
Technical success is defined as the successful placement of the Hot AXIOS™ stent during study procedure. |
2 months (± 15 days)
|
|
Serious Adverse Events
Lasso di tempo: 2 months (± 15 days)
|
Serious adverse events related to the study procedure and/or the Hot AXIOS™ stent. |
2 months (± 15 days)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Jean-Baptiste Chevaux, Central Hospital, Nancy, France
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- E7209
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .